CTS — CTS Corporation

CTS Corporation Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics:

• Sales: $139 million, an 11% increase year-over-year (YoY) and a 1% sequential increase from Q4 2025.
• Diversified Markets: Revenue up 18% YoY; Transportation sales grew 3%.
• Gross Margin: 39.5%, up 250 basis points YoY, driven by operational improvements and favorable end market mix.
• Adjusted Diluted EPS: $0.62, compared to $0.44 in Q1 2025.
• Cash Flow: Generated $17 million in operating cash flow; cash balance of $91 million with $63 million in borrowings.
• Shareholder Returns: $10 million returned through dividends and share buybacks in Q1 2026.

2. Strategic Updates and Business Highlights:

• Diversification Strategy: Continued execution of diversification strategy with strong bookings in industrial and medical markets.
• Medical Market: Sales of $25 million, up 28% YoY, with robust demand in diagnostics and therapeutic applications.
• Aerospace and Defense: Sales of $17 million, up 11% YoY, with expectations for improved government funding in the second half of 2026.
• Industrial Market: Sales of $37 million, up 14% YoY, with strong bookings reflecting stable growth.
• Transportation Market: Sales of $60 million, showing early signs of stability with new business awards secured.

3. Forward Guidance and Outlook:

• Full-Year 2026 Sales Guidance: Narrowed to $560 million to $580 million; adjusted diluted EPS guidance of $2.35 to $2.45.
• Market Expectations: Solid demand anticipated in diversified markets, particularly in medical and industrial sectors, while transportation may face challenges due to geopolitical uncertainties.
• Long-Term Growth: Focus on expanding material formulations and technologies to drive growth in high-quality markets.

4. Bad News, Challenges, or Points of Concern:

• Geopolitical Risks: Ongoing geopolitical conflicts may impact economic conditions and supply chains, particularly in the transportation sector.
• Transportation Market Outlook: Global light vehicle volumes expected to soften; potential production volume declines noted.
• Cost Pressures: Anticipated inflation in oil-derived products and precious metals could impact margins, although efforts are underway to mitigate these effects.
• Aerospace and Defense Bookings: Current bookings down YoY, with expectations of a lag in revenue recognition from government funding.

5. Notable Q&A Insights:

• Revenue Pull-Forward: Management confirmed no revenue was pulled forward into Q1 2026.
• Gross Margin Variability: Medical market exhibits the highest gross margins, with industrial markets closely following; transportation margins are lower.
• Debt Increase: A slight increase in debt attributed to lower operating cash flow and continued share buybacks.
• Capacity Expansion in Medical: Capacity is being expanded in anticipation of double-digit sales growth in the medical sector.
• Defense Funding Expectations: Anticipation of increased government funding in the second half of 2026, with a potential lag in bookings translating to sales.

Overall, CTS Corporation reported a strong first quarter with solid growth across diversified markets, although challenges remain in the transportation sector and due to geopolitical uncertainties. The company maintains a positive outlook for the remainder of 2026, focusing on strategic growth and operational excellence.